Compare BIO-TECHNE Corp (TECH) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Vanguard S&P 500 Growth Index Fund ETF trades at $81.99. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Vanguard S&P 500 Growth Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| TECH | VOOG | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $72.12 | $85.11 |
52-Week Low | $43.31 | $65.32 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
